TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Key facts

Sponsor

Medical College of Wisconsin

Principal Investigator

Mary Horowitz, MD, MS, LCSW

Center for International Blood and Marrow Transplant Research

Intervention

Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate(procedure)

Enrollment

431 enrolled

Eligibility

18 years · All sexes

Timeline

2019 – 2022

Study locations (30)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• City of Hope National Medical Center, Duarte, California, United States
• University of California, San Francisco, San Francisco, California, United States
• Stanford Hospital and Clinics, Stanford, California, United States
• University of Florida College of Medicine (Shands), Gainesville, Florida, United States
• University of Miami, Miami, Florida, United States
• H. Lee Moffitt Cancer Center, Tampa, Florida, United States
• Emory University, Atlanta, Georgia, United States
• Blood & Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States
• University of Chicago, Chicago, Illinois, United States
• Loyola University, Maywood, Illinois, United States
• Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
• Indiana BMT - St. Francis Hospital, Indianapolis, Indiana, United States
• University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
• University of Kansas Hospital, Kansas City, Kansas, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Heart, Lung, and Blood Institute (NHLBI) · Blood and Marrow Transplant Clinical Trials Network · National Cancer Institute (NCI) · National Marrow Donor Program

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06326008
  Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
  Beijing GoBroad Hospital
• RECRUITINGPHASE2NCT06859424
  A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  Center for International Blood and Marrow Transplant Research
• RECRUITINGPHASE2, PHASE3NCT06860269
  A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNCT06895538
  Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
  Peking University First Hospital
• RECRUITINGNANCT06960993
  Mosaic Trial for Stem Cell Transplant Recipients
  Northwestern University
• RECRUITINGPHASE2NCT06816134
  Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE2NCT06608732
  Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
  Institute of Hematology & Blood Diseases Hospital, China
• ACTIVE NOT RECRUITINGNANCT05968963
  Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
  University of Miami

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement →